# MacroGenics clinical trials: 42 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with MacroGenics as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by MacroGenics: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/macrogenics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 16, 2026 | NCT07822399 | A Study of MGC030 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822399) |
| December 12, 2024 | NCT06730347 | A Study of Lorigerlimab in Participants With Advanced Solid Tumors | MacroGenics | Phase 2 | Recruiting | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06730347) |
| December 9, 2024 | NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06723236) |
| February 5, 2024 | NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung... | 394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06242470) |
| May 8, 2023 | NCT05848011 | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | MacroGenics | Phase 2 | Completed | Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent... | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05848011) |
| September 22, 2022 | NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | MacroGenics | Phase 2 | Terminated | Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer... | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05551117) |
| May 5, 2022 | NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | MacroGenics | Phase 1 | Active not recruiting | Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell... | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05362773) |
| March 24, 2022 | NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Completed | Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma... | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05293496) |
| March 2, 2022 | NCT05261191 | A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy | MacroGenics | Phase 1 | Completed | Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1 | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05261191) |
| December 22, 2020 | NCT04678466 | Flotetuzumab Expanded Access Program | MacroGenics | Not applicable | No longer available | Acute Myeloid Leukemia, AML, AML, Adult Recurrent | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04678466) |
| November 18, 2020 | NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | MacroGenics | Phase 2 | Terminated | Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04634825) |
| October 16, 2019 | NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | MacroGenics | Phase 2/3 | Withdrawn | Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04129320) |
| September 9, 2019 | NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | MacroGenics | Phase 2/3 | Completed | Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04082364) |
| December 3, 2018 | NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | MacroGenics | Phase 1 | Completed | Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced... | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03761017) |
| November 2, 2018 | NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | MacroGenics | Phase 1/2 | Terminated | Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult... | 143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03729596) |
| June 27, 2018 | NCT03570918 | MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy | MacroGenics | Phase 1 | Completed | HIV-1-infection | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03570918) |
| May 22, 2018 | NCT03531632 | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | MacroGenics | Phase 1/2 | Completed | Colorectal Cancer Metastatic | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03531632) |
| January 23, 2018 | NCT03406949 | MGD009/MGA012 Combination in Relapsed/Refractory Cancer | MacroGenics | Phase 1 | Completed | Advanced Solid Tumors | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03406949) |
| July 17, 2017 | NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | MacroGenics | Phase 1 | Completed | Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung... | 277 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03219268) |
| December 6, 2016 | NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | MacroGenics | Phase 1 | Completed | Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02982941) |
| February 23, 2016 | NCT02689284 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | MacroGenics | Phase 1/2 | Completed | Gastric Cancer, Stomach Cancer, Esophageal Cancer | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02689284) |
| December 11, 2015 | NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | MacroGenics | Phase 1 | Terminated | Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02628535) |
| July 9, 2015 | NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | MacroGenics | Phase 3 | Completed | HER-2 Positive Breast Cancer, Metastatic Neoplasm | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02492711) |
| June 18, 2015 | NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | MacroGenics | Phase 1 | Completed | Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02475213) |
| March 6, 2015 | NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | MacroGenics | Phase 1 | Completed | Melanoma, Non Small Cell Lung Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02381314) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |
| Phase 1/2 | 5 |
| Phase 2 | 7 |
| Phase 2/3 | 3 |
| Phase 3 | 2 |
| Not applicable | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Terminated | 12 |
| Recruiting | 4 |
| No longer available | 2 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Melanoma | 10 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Squamous Cell Carcinoma of Head and Neck | 7 |
| Pancreatic Neoplasms | 6 |
| Stomach Neoplasms | 6 |
| Colorectal Neoplasms | 5 |
| Breast Neoplasms | 5 |
| Carcinoma, Renal Cell | 5 |
| Urinary Bladder Neoplasms | 4 |
| Diabetes Mellitus, Type 1 | 4 |
| Prostatic Neoplasms, Castration-Resistant | 4 |
| Head and Neck Neoplasms | 4 |
| Colonic Neoplasms | 3 |
| Endometrial Neoplasms | 3 |
| Esophageal Neoplasms | 3 |
| Prostatic Neoplasms | 3 |
| Uterine Cervical Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Small Cell Lung Carcinoma | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Carcinoma, Ovarian Epithelial | 2 |
| Sarcoma | 2 |
| Neoplasm Metastasis | 2 |
| Cholangiocarcinoma | 2 |
| Recurrence | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ear, nose and throat clinics in the United States](https://specstream.ai/data/businesses/ear-nose-and-throat-clinics/united-states)
- [Bars in the United States](https://specstream.ai/data/businesses/bars/united-states)
- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
